Acadia Pharmaceuticals | ACAD - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Cara Therapeutics USD 20.95M 6.92M 2025-12
Corcept Therapeutics USD 637.99M 9.82M 2026-03
Cytokinetics USD -826.57M 166.94M 2026-03
Eisai JPY 898.99B 9.36B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Incyte USD 5.62B 455.37M 2026-03
J&J USD 81.19B 358M 2026-03
Moderna USD 7.41B 1.24B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Prothena USD 312.62M 32.14M 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03